Coherus BioSciences Inc
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
CHRS$0.64-21.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Deficit
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · Total | |||||||||||||||||
| · · Common Stock · · Paid-In · · Comprehensive · · Accumulated · · Stockholders' | |||||||||||||||||
| · Shares · · Amount · Capital · Loss · Deficit · Deficit | |||||||||||||||||
| Balances at December 31, 2024 | 115,614,548 | | $12 | | $1,419,266 | | $(275) | | $(1,550,993) | | $(131,990) | ||||||
| Net loss | | — | | — | | — | | — | | (56,569) | | (56,569) | |||||
| Issuance of common stock upon vesting of restricted stock units ("RSUs") | | 474,410 | | — | | — | | — | | — | | — | |||||
| Taxes paid related to net share settlement of RSUs | | (181,742) | | | — | | | (264) | | | — | | | — | | | (264) |
| Stock-based compensation expense | | — | | — | | 5,353 | | — | | — | | 5,353 | |||||
| Balances at March 31, 2025 | 115,907,216 | | $12 | | $1,424,355 | | $(275) | | $(1,607,562) | | $(183,470) | ||||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · Total | |||||||||||||||||
| · · Common Stock · · Paid-In · · Comprehensive · · Accumulated · · Stockholders' | |||||||||||||||||
| · Shares · · Amount · Capital · Loss · Deficit · Deficit | |||||||||||||||||
| Balances at December 31, 2023 | 112,215,260 | | $11 | | $1,386,312 | | $(248) | | $(1,579,500) | | $(193,425) | ||||||
| Net income | — | | — | | — | | — | | 102,875 | | 102,875 | ||||||
| Issuance of common stock upon exercise of stock options | 174,651 | | — | | 291 | | — | | — | | 291 | ||||||
| Issuance of common stock upon vesting of RSUs | 741,213 | | — | | — | | — | | — | | — | ||||||
| Issuance of common stock under ATM Offering, net of issuance costs | | 650,005 | | | — | | | 1,507 | | | — | | | — | | | 1,507 |
| Taxes paid related to net share settlement of RSUs | | (284,275) | | | — | | | (745) | | | — | | | — | | | (745) |
| Stock-based compensation expense | — | | — | | 7,677 | | — | | — | | 7,677 | ||||||
| Other comprehensive loss, net of tax | — | | — | | — | | (24) | | — | | (24) | ||||||
| Balances at March 31, 2024 | 113,496,854 | | $11 | | $1,395,042 | | $(272) | | $(1,476,625) | | $(81,844) | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.